Speciality Medicines Limited, a speciality pharmaceutical company with diversified export presence across regulated and semi-regulated global markets, announced it has received regulatory approval from the competent health authority in Ethiopia for two additional speciality pharmaceutical formulations:
- Olanzapine Tablets 5 mg (brand name: Olazyn 5)
- Diazepam Tablets 5 mg (brand name: Diazem 5)
With these approvals, the company's total registered product portfolio in the Ethiopian market now stands at 12 formulations. The company also maintains product registrations in Peru with 2 registered formulations. This development strengthens the company's international product portfolio and represents continued progress in regulatory registrations across key export markets.
The information is submitted for the information of the Stock Exchange and the members of the Company.